Khalid Saeed1, Vesa Rahkama1, Samuli Eldfors1, Dmitry Bychkov1, John Patrick Mpindi1, Bhagwan Yadav1, Lassi Paavolainen1, Tero Aittokallio1, Caroline Heckman1, Krister Wennerberg1, Donna M Peehl2, Peter Horvath3, Tuomas Mirtti4, Antti Rannikko5, Olli Kallioniemi1, Päivi Östling1, Taija M Af Hällström6. 1. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. 2. Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. 3. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Synthetic and System Biology Unit, Biological Research Center, Szeged, Hungary. 4. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland. 5. Department of Urology, Helsinki University Hospital, Helsinki, Finland. 6. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. Electronic address: taija.afhallstrom@helsinki.fi.
Abstract
BACKGROUND: Technology development to enable the culture of human prostate cancer (PCa) progenitor cells is required for the identification of new, potentially curative therapies for PCa. OBJECTIVE: We established and characterized patient-derived conditionally reprogrammed cells (CRCs) to assess their biological properties and to apply these to test the efficacies of drugs. DESIGN, SETTING, AND PARTICIPANTS: CRCs were established from seven patient samples with disease ranging from primary PCa to advanced castration-resistant PCa (CRPC). The CRCs were characterized by genomic, transcriptomic, protein expression, and drug profiling. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The phenotypic quantification of the CRCs was done based on immunostaining followed by image analysis with Advanced Cell Classifier using Random Forest supervised machine learning. Copy number aberrations (CNAs) were called from whole-exome sequencing and transcriptomics using in-house pipelines. Dose-response measurements were used to generate multiparameter drug sensitivity scores using R-statistical language. RESULTS AND LIMITATIONS: We generated six benign CRC cultures which all had an androgen receptor-negative, basal/transit-amplifying phenotype with few CNAs. In three-dimensional cell culture, these cells could re-express the androgen receptor. The CRCs from a CRPC patient (HUB.5) displayed multiple CNAs, many of which were shared with the parental tumor. We carried out high-throughput drug-response studies with 306 emerging and clinical cancer drugs. Using the benign CRCs as controls, we identified the Bcl-2 family inhibitor navitoclax as the most potent cancer-specific drug for the CRCs from a CRPC patient. Other drug efficacies included taxanes, mepacrine, and retinoids. CONCLUSIONS: Comprehensive cancer pharmacopeia-wide drug testing of CRCs from a CRPC patient highlighted both known and novel drug sensitivities in PCa, including navitoclax, which is currently being tested in clinical trials of CRPC. PATIENT SUMMARY: We describe an approach to generate patient-derived cancer cells from advanced prostate cancer and apply such cells to discover drugs that could be applied in clinical trials for castration-resistant prostate cancer.
BACKGROUND: Technology development to enable the culture of humanprostate cancer (PCa) progenitor cells is required for the identification of new, potentially curative therapies for PCa. OBJECTIVE: We established and characterized patient-derived conditionally reprogrammed cells (CRCs) to assess their biological properties and to apply these to test the efficacies of drugs. DESIGN, SETTING, AND PARTICIPANTS: CRCs were established from seven patient samples with disease ranging from primary PCa to advanced castration-resistant PCa (CRPC). The CRCs were characterized by genomic, transcriptomic, protein expression, and drug profiling. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The phenotypic quantification of the CRCs was done based on immunostaining followed by image analysis with Advanced Cell Classifier using Random Forest supervised machine learning. Copy number aberrations (CNAs) were called from whole-exome sequencing and transcriptomics using in-house pipelines. Dose-response measurements were used to generate multiparameter drug sensitivity scores using R-statistical language. RESULTS AND LIMITATIONS: We generated six benign CRC cultures which all had an androgen receptor-negative, basal/transit-amplifying phenotype with few CNAs. In three-dimensional cell culture, these cells could re-express the androgen receptor. The CRCs from a CRPC patient (HUB.5) displayed multiple CNAs, many of which were shared with the parental tumor. We carried out high-throughput drug-response studies with 306 emerging and clinical cancer drugs. Using the benign CRCs as controls, we identified the Bcl-2 family inhibitor navitoclax as the most potent cancer-specific drug for the CRCs from a CRPC patient. Other drug efficacies included taxanes, mepacrine, and retinoids. CONCLUSIONS: Comprehensive cancer pharmacopeia-wide drug testing of CRCs from a CRPC patient highlighted both known and novel drug sensitivities in PCa, including navitoclax, which is currently being tested in clinical trials of CRPC. PATIENT SUMMARY: We describe an approach to generate patient-derived cancer cells from advanced prostate cancer and apply such cells to discover drugs that could be applied in clinical trials for castration-resistant prostate cancer.
Authors: Peter Horvath; Nathalie Aulner; Marc Bickle; Anthony M Davies; Elaine Del Nery; Daniel Ebner; Maria C Montoya; Päivi Östling; Vilja Pietiäinen; Leo S Price; Spencer L Shorte; Gerardo Turcatti; Carina von Schantz; Neil O Carragher Journal: Nat Rev Drug Discov Date: 2016-09-12 Impact factor: 84.694
Authors: Xuefeng Liu; Ewa Krawczyk; Frank A Suprynowicz; Nancy Palechor-Ceron; Hang Yuan; Aleksandra Dakic; Vera Simic; Yun-Ling Zheng; Praathibha Sripadhan; Chen Chen; Jie Lu; Tung-Wei Hou; Sujata Choudhury; Bhaskar Kallakury; Dean G Tang; Thomas Darling; Rajesh Thangapazham; Olga Timofeeva; Anatoly Dritschilo; Scott H Randell; Christopher Albanese; Seema Agarwal; Richard Schlegel Journal: Nat Protoc Date: 2017-01-26 Impact factor: 13.491
Authors: Mitchell G Lawrence; Daisuke Obinata; Shahneen Sandhu; Luke A Selth; Stephen Q Wong; Laura H Porter; Natalie Lister; David Pook; Carmel J Pezaro; David L Goode; Richard J Rebello; Ashlee K Clark; Melissa Papargiris; Jenna Van Gramberg; Adrienne R Hanson; Patricia Banks; Hong Wang; Birunthi Niranjan; Shivakumar Keerthikumar; Shelley Hedwards; Alisee Huglo; Rendong Yang; Christine Henzler; Yingming Li; Fernando Lopez-Campos; Elena Castro; Roxanne Toivanen; Arun Azad; Damien Bolton; Jeremy Goad; Jeremy Grummet; Laurence Harewood; John Kourambas; Nathan Lawrentschuk; Daniel Moon; Declan G Murphy; Shomik Sengupta; Ross Snow; Heather Thorne; Catherine Mitchell; John Pedersen; David Clouston; Sam Norden; Andrew Ryan; Scott M Dehm; Wayne D Tilley; Richard B Pearson; Ross D Hannan; Mark Frydenberg; Luc Furic; Renea A Taylor; Gail P Risbridger Journal: Eur Urol Date: 2018-07-23 Impact factor: 20.096
Authors: B M Zeeshan Hameed; Aiswarya V L S Dhavileswarapu; Syed Zahid Raza; Hadis Karimi; Harneet Singh Khanuja; Dasharathraj K Shetty; Sufyan Ibrahim; Milap J Shah; Nithesh Naik; Rahul Paul; Bhavan Prasad Rai; Bhaskar K Somani Journal: J Clin Med Date: 2021-04-26 Impact factor: 4.241